SCHEMBL7188569

SCHEMBL7188569

CC(C)[P](=O)c1ccccc1C(=O)c1c(Cl)cccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.41
CNR1 P21554 3/20 0.39
ALDH1A1 P00352 3/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
RORC P51449 7/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
PBRM1 Q86U86 1/20 0.37
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7181413 0.86 CNR2 (0.40) CNR2CNR1ALDH1A1CES2CES1
SCHEMBL7190118 0.83 CNR2 (0.38) CNR2CNR1ALDH1A1CYP1A2CYP3A4
SCHEMBL7186443 0.81 CNR2 (0.39) CNR2CNR1ALDH1A1CES2CES1
SCHEMBL7174871 0.80 CNR2 (0.38) CNR2CNR1ALDH1A1CES2CES1
SCHEMBL7180810 0.79 CA12 (0.44) CNR2CNR1ALDH1A1
SCHEMBL7183502 0.79 CNR2 (0.38) CNR2CNR1ALDH1A1CES2CES1
SCHEMBL7183932 0.78 CNR2 (0.39) CNR2ALDH1A1RORCCYP3A4CYP2C9
SCHEMBL7182214 0.78 HPGD (0.42) CNR2CNR1ALDH1A1CYP1A2CYP2C19
SCHEMBL7189090 0.76 CNR2 (0.35) CNR2CNR1ALDH1A1RORCCYP1A2
SCHEMBL7174823 0.75 RORC (0.42) CNR2CNR1ALDH1A1RORCCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 CNR2 1721/4885CNR1 651/4885ALDH1A1 3416/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 CNR2 1343/4885CNR1 583/4885ALDH1A1 3984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.